TEVA Q3 2017 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena

TEVATeva Pharmaceutical Industries Limited

$36B

Q3 2017 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$5.6B+0.8% YoY

Gross Profit

$2.6B47.1% margin

Operating Income

$378M6.7% margin

Net Income

$530M9.4% margin

EPS (Diluted)

$0.52

QoQ Revenue Growth

-1.3%

Cash Flow

Operating Cash Flow

$1.1B

Free Cash Flow

$905M

Stock-Based Comp.

$31M

Balance Sheet

Total Assets

$86.1B

Total Liabilities

$55.8B

Stockholders' Equity

$28.7B

Cash & Equivalents

$680M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5.6B	$5.6B	+0.8%
Gross Profit	$2.6B	$2.8B	-5.6%
Operating Income	$378M	$765M	-50.6%
Net Income	$530M	$348M	+52.3%